Click on a filter below to refine your search. Remove a filter to broaden your search.
Reductions seen in death from a variety of causes; PHDI scores were also associated with environmental impact
At the prespecified 104-week time point, semaglutide was associated with a lesser decline in eGFR than placebo.
Similar benefits were seen for all-cause mortality and cardiovascular disease prevention.
The benefits include a better cardiometabolic risk profile as well as lower mortality.
Hormone therapy was no aid for cardiovascular disease prevention, and calcium/vitamin D supplementation was no aid for universal fracture prevention.
The finding was seen for processing speed and cardiovascular health in Black women but not white women.